Abstract：Objective To observe the clinical efficacy of Hexue Mingmu tablets combined with anti-vascular endothelial growth factor (VEGF) drug (ranibizumab) in the treatment of wet age-related macular degeneration (wAMD).Methods Ninety-six patients (96 eyes) with wAMD were randomly divided into two groups using the random number table method: the treatment group (48 eyes)that was treated with anti- VEGF intravitreal injection combined with Hexue Mingmu tablets and the control group(48 eyes) treated with anti-VEGF intravitreal injection alone. Both groups were treated for three consecutive months. The best corrected visual acuity (BCVA), central retinal thickness in the macular area (CRT), macular hemorrhage area, exudation area and cumulative injury area were observed in both groups for 3 months. The recurrence of macular edema was analyzed and evaluated statistically after the follow-up.Results (1)After 3 months of treatment, BCVA was increased in both groups(t=8.320 vst=4.689),especially in the treatment group. After 6 months of treatment, BCVA was increased in both groups (t=7.909 vst=3.808) and the difference between the two groups was statistically significant.(2)After 3 months of treatment, CRT was decreased in both groups(t=16.864 vst=14.175), but there was no statistically significant difference between the two groups. After 6 months of treatment, CRT was decreased in both groups, especially in the treatment group, but there was statistically significant difference between the two groups.(3) After 3 months of treatment, the areas of macular hemorrhage, exudation and cumulative injury in both groups were significantly smaller, especially in the treatment group (P<0.05). (4) The recurrence rate was significantly different between the two groups (χ2=4.937,P<0.05).Conclusions The clinical efficacy of anti-VEGF intravitreal injection combined with Hexue Mingmu tablets in the treatment of age-related macular degeneration is confirmed, and the combined treatment is superior to the single anti-VEGF intravitreal injection in the control of macular hemorrhage and edema recurrence.
Pedrosa A C, Reis S A, Pinheiro C J, et al. Treatment of neovascular age-related macular degeneration with anti-VEGF agents: retrospective analysis of 5-year outcomes[J]. Clin Ophthalmol,2016,29(10):541-546.
2019, Vol. 30 
